Dumont & Blake Investment Advisors LLC Purchases New Shares in Autolus Therapeutics plc (NASDAQ:AUTL)

Dumont & Blake Investment Advisors LLC purchased a new stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL) in the 4th quarter, Holdings Channel reports. The fund purchased 15,000 shares of the company’s stock, valued at approximately $35,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. ProShare Advisors LLC acquired a new position in Autolus Therapeutics in the second quarter valued at approximately $43,000. Arkadios Wealth Advisors purchased a new position in shares of Autolus Therapeutics in the 4th quarter valued at about $47,000. Capstone Investment Advisors LLC acquired a new stake in Autolus Therapeutics during the 3rd quarter worth approximately $51,000. Avanza Fonder AB acquired a new position in Autolus Therapeutics during the fourth quarter worth $75,000. Finally, Herbst Group LLC purchased a new position in Autolus Therapeutics during the third quarter worth $91,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Price Performance

AUTL stock opened at $2.20 on Friday. The stock has a market capitalization of $585.40 million, a price-to-earnings ratio of -1.82 and a beta of 2.05. The business’s fifty day moving average price is $2.54 and its two-hundred day moving average price is $3.46. Autolus Therapeutics plc has a fifty-two week low of $2.07 and a fifty-two week high of $7.37.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the business earned ($0.26) earnings per share. Research analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on AUTL. Redburn Atlantic upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research note on Friday, November 15th. Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, January 13th. Finally, The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.